Author: Zacks Small Cap Research

1 2 3 21 10 / 202 POSTS
By David Bautz, PhDNYSE:APHBREAD THE FULL APHB RESEARCH REPORTBusiness UpdateMeeting with the FDA to Determine Regulatory Path for AB-SA01 and AB-PA01On August 9, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) provided a business update concerning the ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateContraFect Corp. (NASDAQ:CFRX) is currently conducting a Phase 2 clinical trial of CF-301, the company’s lead lysin product candidate, in patients with bacteremia, includi ...
NASDAQ:CKPTCheckpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, Canada. CK-101 is the company’s lead candidate ...
By Steven Ralston, CFANASDAQ:DSKEREAD THE FULL DSKE RESEARCH REPORTSUMMARY OF RECENT EVENTS‣ On August 9th, Daseke (NASDAQ:DSKE) announced financial results for the second quarter ending June 30, 2018.     • Total revenues increased 91.0%, primarily ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateVK5211 UpdateIn 2017, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced positive topline results from the Phase 2 study of VK5211, a selective androgen receptor modulator ...
By David Bautz, PhDNASDAQ:OPNTREAD THE FULL OPNT RESEARCH REPORTBusiness UpdateOPNT003 UpdateEarlier in 2018, Opiant (NASDAQ:OPNT) announced the receipt of a $7.4 million grant from the National Institute on Drug Abuse (NIDA) to fund the development ...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ2 2018 Results: Huge Beat to Our #s. Huge Upward Revisions to Our Model and Price Target…Semler’s (OTC:SMLR) results in each of the last few quarters have indicated that the company could ...
By Lisa ThompsonNASDAQ:RVLTREAD THE FULL RVLT RESEARCH REPORTRevolution Lighting Technologies (NASDAQ:RVLT) missed its revenue guidance by reporting Q2 revenues of $36.4 million versus $43.4 million a year ago, down 16%. A few large opportunities tha ...
By John Vandermosten, CFANASDAQ:RXIIOn August 1st RXi Pharmaceuticals (NASDAQ:RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. The primary outcome for the trial was to determine t ...
OTC:CVSISan Diego, California-based CV Sciences, Inc. (OTC:CVSI) manufactures hemp-based phytocannabinoids including cannabidiol (CBD) oil and also develops specialty pharmaceutical therapeutics. The company reported 2Q18 results yesterday that refle ...
1 2 3 21 10 / 202 POSTS